1. Introduction
===============

Hypermetabolism is a significant consequence of severe trauma such as burns \[[@B1-metabolites-02-00458]\], as well as critical illnesses such as cancer \[[@B2-metabolites-02-00458]\]. It persists in parallel to, or beyond, the original pathology for many months as an often-fatal comorbidity. Prolonged hypermetabolism is characterized by increased resting energy expenditure and severe muscle wasting due to a negative nitrogen balance. The underlying mechanisms that control the onset and resolution of the hypermetabolic response are unknown. Therefore, current treatments are directed at symptoms which are metabolic, endocrine, and immune in nature.

Increasing nutritional energy delivery and protein intake only partially alleviate the loss of lean body mass \[[@B3-metabolites-02-00458],[@B4-metabolites-02-00458]\]. Experimental approaches to overcome the deleterious effects of hypermetabolism have been used with varying success, including glutamine and arginine supplementation \[[@B5-metabolites-02-00458],[@B6-metabolites-02-00458]\]; combinatorial nutritional therapies using a diet high in vitamins, protein, amino acids, and ω-3 fatty acids \[[@B7-metabolites-02-00458]\]; peroxisome proliferator activated receptor-α agonists to improve fat oxidation and mitochondrial activity \[[@B8-metabolites-02-00458]\]; as well as antioxidant and anti-inflammatory agents \[[@B9-metabolites-02-00458]\]. Modulation of insulin action \[[@B10-metabolites-02-00458]\], direct insulin therapy \[[@B11-metabolites-02-00458],[@B12-metabolites-02-00458]\], administration of other anabolic agents \[[@B13-metabolites-02-00458]\], as well as β-blockers \[[@B14-metabolites-02-00458]\] have also produced significant improvements, but are inherently impractical in the long-term, and in some cases produce undesirable, potentially fatal, side effects \[[@B15-metabolites-02-00458],[@B16-metabolites-02-00458]\].

Rational design and optimization of nutritional therapies can be achieved by targeting the interconnected metabolic network and regulatory pathways impacted by hypermetabolism \[[@B17-metabolites-02-00458],[@B18-metabolites-02-00458],[@B19-metabolites-02-00458],[@B20-metabolites-02-00458],[@B21-metabolites-02-00458]\], thereby having a broad impact on the metabolome, and subsequently altering the physiome at the genomic and proteomic levels. Hence an understanding of the connections among individual metabolites and the overall injury physiome is necessary to rationally design metabolic interventions. While the advances in metabolomics and metabonomics are starting to present an ever-increasing amount of data, the capability to quantitatively and accurately predict the metabolic effects of nutritional supplements in order to design the kind of combination therapies that could treat hypermetabolism and other metabolic conditions remains absent.

There are a variety of techniques to extract knowledge from "omics" data. These include pattern identification methods such as clustering and principal component analysis (PCA) typically applied to time-series mRNA microarray data to identify key trendlines \[[@B22-metabolites-02-00458]\]; network analysis to identify correlations between genes/metabolites \[[@B17-metabolites-02-00458]\]; and marker discovery \[[@B23-metabolites-02-00458]\], which utilizes a combination of techniques above to correlate disease with a specific measured variable. Metabonomics in particular focuses on the metabolic analysis of the consequences of a perturbation, such as disease and medication. While metabonomics of toxicity \[[@B24-metabolites-02-00458]\] and pharmaceuticals \[[@B25-metabolites-02-00458]\] is an emerging field, there are few studies performing rigorous metabolic analyses as a function of extent of injury or disease \[[@B23-metabolites-02-00458],[@B26-metabolites-02-00458]\].

While there has been some effort to develop analytical mathematical models for hypermetabolism \[[@B27-metabolites-02-00458],[@B28-metabolites-02-00458]\], predictive models remain absent. There are however efforts to develop such approaches, for instance Flux Balance Analysis (FBA), to identify the metabolic causes of fat accumulation in hepatocytes \[[@B29-metabolites-02-00458],[@B30-metabolites-02-00458]\]; similar approaches could potentially predict metabolic responses to potential interventions, such as amino acid supplements and hence rationally develop combination therapies in hypermetabolism. However, in vivo hypermetabolism remains a mostly clinical observation, and quantitative measures of hypermetabolism to define the extent of burn injury are necessary for use of optimization-based FBA models.

The objective of this study was to identify sensitive indicators that correlate with the severity of injury and that can be measured from blood samples. For this purpose, we used rat models of cutaneous burn injury of increasing size, and analyzed metabonomic data on postburn day 4. We identified VLDL and acetoacetate in the circulation as being particularly sensitive to the extent of burn injury, and thus could serve as a quantitative measure of the grade of hypermetabolism.

2. Experimental Methods
=======================

Briefly, male Sprague--Dawley rats (Charles River Labs) weighing between 270 g and 300 g at time of burn, were subjected to a third degree cutaneous burn injury (*i.e.*, depth of injury spans the entire thickness of the skin) covering 20% of the Total Body Surface Area (TBSA) (dorsal burn only) or 40% TBSA (burn on dorsum and abdomen) by contacting the skin with water at 100 °C. Sham-treated animals were handled identically to the burn groups, except that room temperature water was used. After injury, animals were immediately resuscitated with an intraperitoneal saline injection (20 mL/kg per rat) and allowed to recover in individual cages. Animals were weighed daily and food consumption was monitored. On the third day following the injury, all rats were fasted overnight in preparation for the blood samples to be taken on Day 4 as described in detail elsewhere \[[@B21-metabolites-02-00458]\]. Briefly, on day 4, each rat was anesthetized and blood flow through each of the major blood vessels entering the liver (the portal vein, PV, and hepatic artery, HA, USA) were measured using a perivascular ultrasonic flow-probe (Transonic Systems, Ithaca, NY, USA). The sum of flow rates into the liver was assumed to equal the flow rate out of the hepatic veins into the suprahepatic vena cava (SHVC). Following flow rate measurements, blood samples from the hepatic veins and PV were taken, followed by arterial blood. Blood samples were analyzed for blood gases and pH using a Rapidlab Blood Gas Analyzer 865 (Bayer). Standard reagent kits were used to determine plasma glucose (Stanbio No. 1075-825), urea (Stanbio No. 0580), and lactate (Trinity Biotech USA No. 735-10). The ketone bodies acetoacetate and β-hydroxybutyrate were measured enzymatically by following the appearance or disappearance of NADH upon the addition of β-hydroxybutyrate dehydrogenase (Sigma), respectively. Nineteen of the common amino acids (except tryptophan) plus ornithine and ammonia were measured using a Waters HPLC apparatus (Waters Co. Milford, MA, USA). ELISA techniques were used to detect albumin (Sigma) and insulin (Crystal Chem Inc No. INSKR020). Alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin, blood urea nitrogen, and creatinine, HDL, LDL, VLDL, cholesterol and triacylglycerols were measured using a Piccolo Comprehensive Metabolic Panel (Abaxis, Inc., Union City, CA, USA). Finally, the liver was excised and weighed. Fluxes across the liver were subsequently determined as the difference between in- and effluxes, calculated per vessel as the product of metabolic concentration and flow rate normalized to the weight of the liver. Note that early injury markers, such as cytokines and tissue damage, have shown a clear linear trend with increasing burn severity \[[@B31-metabolites-02-00458],[@B32-metabolites-02-00458]\]; however, we sought variables that were less likely to have a transient response or a response subsequently complicated by sepsis so we only employed metabolic markers still visible 4 days after injury for consideration as indicators of burn injury.

3. Numerical Methods
====================

3.1. Theoretical Aspects
------------------------

The primary goal of this study was to identify key metabolites that are strongly correlated to the hypermetabolism in the form of a predictive model of the degree of burn injury. However, since metabolic data suffer from the existence of a high degree of correlation \[[@B17-metabolites-02-00458]\], a straightforward statistical analysis (e.g., ANOVA), is very limited. Many variables will be identified as correlated to injury because of their own interrelationships. Therefore, a critical issue is to identify the *key* variables involved, which may be defined as the minimum number of variables that can explain the metabolic response to injury. For the purposes of this work, this problem can equivalently be stated as the identification of the minimum number of variables necessary to construct an accurate model that can predict the degree of injury from metabolic data.

It should be noted that in the absence of a mechanistic description of the effects of injury, empirical mathematical models are necessary, which further increases the problem of complexity as the type of model to be used becomes another variable. Therefore, the problem of constructing an "index of burn injury severity" is a multiobjective problem where the task is to simultaneously: (i) select and train the best mathematical model; (ii) maximize model accuracy by selecting the variables to use; (iii) minimize the number of variables in the model. To achieve this goal, we designed a novel algorithm to identify the metabolites that are most indicative of injury grade, as outlined in [Figure 1](#metabolites-02-00458-f001){ref-type="fig"} and discussed in detail below.

![The burn-injury indicator identification algorithm.](metabolites-02-00458-g001){#metabolites-02-00458-f001}

*Clustering of Dose-Response Patterns*. The first step in the algorithm is clustering in order to group the metabolites responding similarly to increased injury, which serves multiple purposes. Clustering serves as the first step in reducing the problem dimensionality, as all metabolites collected in one group can be considered to be regulated by the same mechanisms, and ideally can be considered as a single variable (or, a single metabolite can adequately represent all others in the same cluster). Therefore, the number of clusters necessary to represent the data presents an adequate first-guess for the ideal number of variables to capture the entire metabolic response. In addition, since we have obtained dose-response data rather than a simple injury vs. non-injury comparison, clustering also identifies the major patterns observed in response to increasing levels of burn injury, which enables incorporating a physiological interpretation prior to identification of the burn-grade indicators.

A critical issue in clustering is the determination of the number of clusters, either defined directly as a parameter (as in k-means clustering which is employed here) or indirectly (as in hierarchical clustering). We utilized a tandem approach to determine the optimum number of clusters, combining analysis of explained variance (here measured as sums of point-to-centroid distances of all clusters) and the separation of individual clusters (assessed through silhouette analysis) \[[@B33-metabolites-02-00458]\]. It should be noted that the tandem use is necessary: in clustering, by definition, as the number of clusters increases, the error of clustering is reduced, until each instance (*i.e.*, patient) itself is a cluster and the error is zero, which obviously is of little value. An alternative criterion to identify a good number of clusters that is commonly employed is the marginal gain of adding a cluster, which often displays "elbows" where the marginal value decreases steeply. However, often there are multiple elbows and so multiple choices of good numbers of clusters. To differentiate between such potential solutions, we employed the silhouette analysis, which is a measure of separation for clusters. Briefly, the silhouette value is a measure of how close each point in one cluster is to points in the neighboring clusters. This measure ranges from +1, indicating points that are very distant from neighboring clusters, through 0, indicating points that are not distinctly in one cluster or another, to −1, indicating points that are probably assigned to the wrong cluster \[[@B33-metabolites-02-00458]\]. Combining the marginal value and silhouette methods, it is possible to assess marginal return and mean silhouette values as a function of number of clusters, and identify the number of clusters that simultaneously have a local maxima in their silhouette value and display a decrease in cluster error. This is in essence a visual analysis of the two charts to identify the minimum number of clusters

*Identification of Independent Patterns*. Identified patterns reveal the key trends in the dose response. In mRNA analysis, the co-regulated gene expression reveals information regarding genetic control motifs \[[@B34-metabolites-02-00458]\]. The situation is more complex in metabonomics, as correlations exist due to a variety of reasons such as simple stoichiometric dependencies \[[@B17-metabolites-02-00458]\]. Accordingly, it is necessary to extract the actual number of independent patterns in order to filter out these metabolic correlations that are not of primary interest for this study.

To achieve this purpose, a Singular Value Decomposition (SVD) was performed on the cluster centroids: Briefly, each cluster was expressed as a vector (the cluster median for each level of injury was an entry in the vector), and the vectors were augmented to form a cluster centroid matrix. SVD was performed to identify the number of independent patterns, which can be used to explain the remaining patterns. This is in effect a rank analysis, but direct analysis of singular values enables identification of marginally non-zero singular values, which are likely artifacts of measurement error and/or statistical clustering rather than major patterns in the injury response. The number of distinct singular values that are also non zero (\>10^−2^, a heuristically chosen limit) was chosen as the number of independent clusters.

The product of this tandem approach is: (i) identified patterns in the injury response; and (ii) the minimum number of patterns that can explain the entire response, which is interpreted here as equivalent to the minimum number of variables that are necessary to construct an index of injury.

It is worth noting that this two-step hybrid procedure to reduce the problem dimensionality has problem-specific advantages over conventional dimension reduction methods such as PCA or Linear Discriminant Analysis (LDA). PCA is the optimum method for elimination of collinearities present in the data, but is not optimized for class separability, hence will be insensitive to the presence of patterns due to elevated injury. LDA is an elegant and "context sensitive" solution, but assumes linearity, which may or may not be valid in burn injury. The method employed here incorporates a sophisticated model selection process, including nonlinear classifiers such as Artificial Neural Networks.

*Pattern Analysis*. The analysis of clustering provides several layers of information. The independent pattern analysis performed above provides the ideal number of variables that are necessary to capture the injury response. Detailed analysis of cluster membership may reveal further physiological information; for instance, in this work we used changing cluster membership between the liver inlets (hepatic artery and portal vein) and outlet (vena cava) for any particular metabolite as an indicator of altered liver function due to burn injury.

*Variable Elimination and Model Selection*. For each model (classifier) type considered, the variable elimination task involves finding an optimum list of variables that maximizes the model's prediction accuracy. N-fold cross-validation accuracies were used to estimate the real-world accuracy for the trained regression models \[[@B35-metabolites-02-00458],[@B36-metabolites-02-00458]\]: data are separated into N subsets; model training and validation is performed N-times, and in each run one of the subsets is used only for validation and the rest for model training. N-fold cross validation significantly reduces variability in accuracy estimates due to uneven validation data selections as all data is reused for testing the model accuracy. Multiple repetitions of the n-fold cross validation ensure that the selection process for the subsets does not affect the results.

For a given set of variables, comparison of alternative regression models is a straightforward task that can be based on the cross-validation results. If the number of variables is preset, the variable elimination is also a straightforward, albeit computationally intensive procedure: this problem is a combinatorial-optimization problem, where a set number of variables are chosen to maximize cross validation accuracy. In this work, we employed the variable selection algorithm in WEKA which employs a genetic algorithm to select the best variables to maximize the cross-validation accuracy for each classifier. This was followed by a ranking subroutine (Best-first algorithm in WEKA, a greedy step-climbing algorithm augmented with backtracking facility) which was used to select only the preset number of variables.

However, the number of variables is typically a confounding factor. Briefly, the training accuracy improves in regression as the number of variables/free parameters increases, but this results in overtraining, such that the model is not valid for real data (*i.e*., the model is not *generalizable*), hence cross-validation accuracy will decrease after a certain point. The straightforward approach is to evaluate the cross-validation accuracy as a function of the number of variables used in the model, and choose the minimum number of variables that provide a high cross-validated accuracy, but this process is a very computationally intensive task since the variable elimination described above has to be repeated for each set number of variables, and this process has to be repeated for all possible models. Further, there are often multiple good solutions that have very similar accuracies. Therefore, in choosing the best combination of model, variables, and accuracy, determination of the proper weights of these competing objectives becomes a subjective decision.

By comparison, the number of independent patterns identified as described above, provides a simple criterion that can be determined through an objective and quick process. This approach also avoids issues during selection of the best regression model (*i.e.*, the decision of which model to use for the index of hypermetabolism), since number of variables employed by each model becomes an *a priori* set quantity that is equal for all tested alternatives.

3.2. Methods
------------

*Data Preprocessing*. The data per rat include metabolite concentrations of each of the PV, HA, and hepatic veins, and metabolic fluxes across the liver on day 4 post-burn. To eliminate outliers, variables with values beyond the median ± 2 × interquartile range for the group were considered as missing \[[@B37-metabolites-02-00458]\]. Since individual rat data are used in the construction of a hypermetabolism index, rats with \>30% missing extracellular metabolite measurements were removed from the experimental dataset. Overall, 7 out of 12, 7/12, and 7/13 rat datasets were retained for the sham, 20% and 40% TBSA burn conditions, respectively. The missing values were replaced by the median of the measurements of that group. This resulted in a data matrix of 165 measurements on each of 21 animals.

*Analysis*. To identify major patterns in the dose response to burn, k-means clustering was performed in MATLAB. The average of each variable was calculated for each burn group (sham, 20%, 40%). Each variable was normalized to \[−1 1\] interval. The Euclidian distance was used as the clustering performance which provided better silhouette values compared to other distance measures (results not shown). Each clustering was run with \>10 replicates and that the cluster means and their membership remained similar was confirmed (results not shown). It was observed that the changes in the cluster centroids were negligible between clustering runs, an indicator that the number of clusters was well chosen and cluster separation achieved was close to ideal. The centroid of each cluster was identified as the dose-response pattern.

Training, cross-validation, and selection of regression models were performed in WEKA data mining software \[[@B36-metabolites-02-00458]\]. The analysis was performed on per-rat data. The following classifiers were tested: Linear Regression (LR), normalized gaussian Radial Basis Function Network (RBFN), Neural Network (NN) (multilayer perceptron), Sequential Minimal Optimization algorithm for training a support vector Regression model (SMOR), M5P Decision Tree (M5P-DT), Decision Table (DT), M5 Rules (M5-R). For each method, variable selection was performed as described above. The accuracy of each regression model was then evaluated via five 10-fold cross validations, where all randomizable variables in the model, as well as the partitioning of data into 10 folds, were randomized.

4. Results
==========

*Clustering*. Analysis of the mean silhouette results demonstrated that increase from four to six cluster increased clusters separation only marginally (2.2%), hence four was chosen as the optimum number ([Figure 2](#metabolites-02-00458-f002){ref-type="fig"}). [Figure 3](#metabolites-02-00458-f003){ref-type="fig"} displays the results of clustering along with the centroids of each cluster as a function of burn injury degree. [Table 1](#metabolites-02-00458-t001){ref-type="table"} lists all the variables included in the analysis, their averages for each burn group, and the cluster membership for each variable.

![Cluster analysis indicates four distinct patterns present in metabolic profiles: (**A**) Number of clusters *vs.* sum distance from cluster centroid. (**B**) Number of clusters *vs.* silhouette value. (**C**) Silhouette values for each metabolite within the four clusters identified; a value of 1 indicates the metabolite profile is identical to the cluster centroid; −1 indicates the metabolite displays a perfect inverse profile.](metabolites-02-00458-g002){#metabolites-02-00458-f002}

![Identified Clusters. (**A**--**D**) Profile of metabolites classified within clusters 1--4. (**E**--**H**) Centroids (patterns) for each cluster.](metabolites-02-00458-g003){#metabolites-02-00458-f003}

metabolites-02-00458-t001_Table 1

###### 

Variables included in analysis and cluster membership.

  Variable                                                 Vessel   Cluster   Sham (median ± IQR)   20%(median ± IQR)   40%(median ± IQR)
  -------------------------------------------------------- -------- --------- --------------------- ------------------- -------------------
  Arginine                                                 HA       1         110.51 ± 10.239       182.13 ± 83.525     181.24 ± 14.245
  Creatinine (Cre)                                         HA       1         0.2 ± 0               0.2 ± 0.05          0.2 ± 0
  Cysteine                                                 HA       1         15.76 ± 6.57          21.36 ± 0.92        25.55 ± 1.524
  Fraction of Carboxyhemoglobin (FCOHb)                    HA       1         7.9 ± 0.35            8.3 ± 1.5           8.5 ± 0.8
  Fraction of Methlyated hemoglobin (Fmeth)                HA       1         0 ± 0                 0 ± 0               0 ± 0
  Low Density Lipoprotein (LDL)                            HA       1         18 ± 14               22 ± 6              38 ± 8.75
  Ornithine                                                HA       1         98.84 ± 22.359        117.73 ± 2.414      139.78 ± 12.129
  Total Bilirubin (TBIL)                                   HA       1         0.3 ± 0.075           0.3 ± 0             0.3 ± 0.1
  Total cholesterol/HDL ratio (TC/H)                       HA       1         2.1 ± 0.1             2.2 ± 0.3           2.2 ± 0.05
  Arginine                                                 PV       1         113.3 ± 104.288       227.17 ± 42.862     223.04 ± 5.409
  Aspartate Amino Transferase (AST)                        PV       1         74 ± 16.5             83 ± 32.5           88 ± 27.5
  AST/ALT                                                  PV       1         1.73 ± 0.599          1.91 ± 0.82         2.1 ± 0.893
  Cholesterol                                              PV       1         56 ± 24.5             74.5 ± 21.75        79 ± 10
  Creatinine (Cre)                                         PV       1         0.2 ± 0               0.2 ± 0.05          0.2 ± 0
  Cysteine                                                 PV       1         14.89 ± 2.658         16.46 ± 1.543       16.55 ± 1.155
  Fraction of Carboxyhemoglobin (FCOHb)                    PV       1         7.2 ± 0.8             8.1 ± 1             7.7 ± 0.75
  Flow Rate                                                PV       1         9 ± 9.226             20.5 ± 10.2         22 ± 6.5
  Fraction of Methlyated hemoglobin (Fmeth)                PV       1         0 ± 0                 0 ± 0.05            0 ± 0.1
  Isoleucine                                               PV       1         91.03 ± 34.218        100.74 ± 12.663     99.65 ± 3.513
  Low Density Lipoprotein (LDL)                            PV       1         17 ± 6                30 ± 6              42.5 ± 9.5
  Leucine                                                  PV       1         243.09 ± 67.215       308.18 ± 25.007     336.71 ± 23.168
  Lysine                                                   PV       1         215.96 ± 92.604       234.02 ± 21.353     269.19 ± 20.227
  Phenylalanine                                            PV       1         58.35 ± 9.465         65.69 ± 4.891       66.63 ± 7.422
  Total Bilirubin (TBIL)                                   PV       1         0.3 ± 0.05            0.3 ± 0.05          0.3 ± 0.05
  Total cholesterol/HDL ratio (TC/H)                       PV       1         1.9 ± 0.1             2 ± 0.1             2.3 ± 0.05
  Total CO2                                                PV       1         20 ± 4.5              23 ± 0              23 ± 3.5
  Threonine                                                PV       1         175.33 ± 61.707       219.96 ± 60.936     228.44 ± 50.882
  Tyrosine                                                 PV       1         62.95 ± 8.409         73.73 ± 6.036       78.49 ± 8.038
  Valine                                                   PV       1         176.6 ± 62.552        206.26 ± 19.143     206.03 ± 4.825
  Arginine                                                 SHVC     1         62.27 ± 2.077         211.01 ± 23.971     206.12 ± 37.934
  AST/ALT                                                  SHVC     1         2.03 ± 0.786          2.41 ± 1.036        2.36 ± 0.913
  Blood Urea Nitrogen (BUN)                                SHVC     1         13 ± 2                15.5 ± 1.5          17.5 ± 2.5
  Cholesterol                                              SHVC     1         49 ± 10               55 ± 22             74 ± 7
  Creatinine (Cre)                                         SHVC     1         0.2 ± 0               0.2 ± 0.05          0.2 ± 0
  Cysteine                                                 SHVC     1         12.07 ± 0.595         16.68 ± 2.042       18.37 ± 2.285
  Flow Rate                                                SHVC     1         9.5 ± 9.255           20.9 ± 10.2         22.2 ± 6.7
  Fraction of Methlyated hemoglobin (Fmeth)                SHVC     1         0.25 ± 0.25           0.3 ± 0.15          0.3 ± 0.3
  Isoleucine                                               SHVC     1         79.1 ± 12.184         103.88 ± 12.065     103.42 ± 8.164
  Potassium (K)                                            SHVC     1         3.2 ± 0.95            4.2 ± 0.95          4 ± 1.15
  Low Density Lipoprotein (LDL)                            SHVC     1         17 ± 10.25            23 ± 6              36 ± 0
  Ornithine                                                SHVC     1         77.44 ± 19.421        89.36 ± 35.165      123.36 ± 14.992
  Total Bilirubin (TBIL)                                   SHVC     1         0.3 ± 0.05            0.3 ± 0             0.3 ± 0.05
  Total cholesterol/HDL ratio (TC/H)                       SHVC     1         2.05 ± 0.2            2.1 ± 0.1           2.2 ± 0
  Valine                                                   SHVC     1         121.63 ± 54.408       204.83 ± 24.603     206.6 ± 21.909
  AST/ALT                                                  HA       2         2 ± 0.752             2.48 ± 1.04         2.07 ± 0.733
  Chloride (Cl)                                            HA       2         109 ± 10.5            114 ± 19            109 ± 10.5
  Fraction of Oxyhemoglobin (FO2Hb)                        HA       2         91.2 ± 4.85           91.5 ± 2.15         84.8 ± 8.35
  Sodium (Na)                                              HA       2         143 ± 6               153 ± 16.5          142 ± 9
  Partial pressure of CO2 (pCO2)                           HA       2         43.95 ± 4.9           51.3 ± 12.65        46.8 ± 1.4
  pH                                                       HA       2         7.27 ± 0.059          7.3 ± 0.034         7.27 ± 0.042
  Partial Oxygen pressure (PO2)                            HA       2         106.2 ± 19.85         117.3 ± 18.5        100.35 ± 35.525
  Tyrosine                                                 HA       2         79.81 ± 17.969        88.17 ± 6.785       78.64 ± 8.325
  Acetoacetate                                             PV       2         115.35 ± 115.91       134.15 ± 91.278     50.81 ± 115.089
  Alanine                                                  PV       2         391.58 ± 10.724       452.9 ± 113.48      395.22 ± 95.64
  Alanine Amino Transferase (ALT)                          PV       2         42 ± 11               46 ± 4.5            42 ± 4.5
  β-hydroxybutyrate                                        PV       2         81.41 ± 87.551        103.82 ± 64.453     88.47 ± 49.107
  Blood Urea Nitrogen (BUN)                                PV       2         12 ± 5.5              16 ± 2.5            14 ± 3.5
  Fraction of Oxyhemoglobin (FO2Hb)                        PV       2         73.6 ± 12.4           82.7 ± 18.75        73.7 ± 15.2
  Glucose                                                  PV       2         143 ± 126.5           183 ± 55.5          147 ± 48.5
  Potassium (K)                                            PV       2         3.7 ± 1.25            4.1 ± 0.7           3.7 ± 0.6
  Partial pressure of CO2 (pCO2)                           PV       2         55.6 ± 3.05           60.55 ± 5.5         57.5 ± 2.3
  pH                                                       PV       2         7.28 ± 0.01           7.3 ± 0.077         7.26 ± 0.028
  Acetoacetate                                             SHVC     2         126.21 ± 27.78        126.21 ± 13.89      30.96 ± 95.246
  Aspartate Amino Transferase (AST)                        SHVC     2         84 ± 16               85 ± 13             80 ± 31
  Fraction of Oxyhemoglobin (FO2Hb)                        SHVC     2         23.3 ± 5.55           28.7 ± 17.65        14.1 ± 14
  Leucine                                                  SHVC     2         218.34 ± 52.758       261.92 ± 91.466     210.42 ± 147.222
  pH                                                       SHVC     2         7.29 ± 0.02           7.32 ± 0.055        7.25 ± 0.021
  Partial Oxygen pressure (PO2)                            SHVC     2         27.2 ± 0.725          41.9 ± 15.6         15.1 ± 11.4
  Alkaline phosphatase (ALP)                               HA       3         192 ± 96.5            113 ± 21            194 ± 74
  Aspartate Amino Transferase (ALT)                        HA       3         49.5 ± 14.25          36 ± 7.5            39 ± 11.5
  β-hydroxybutyrate                                        HA       3         183.61 ± 194.894      65.45 ± 39.132      165.2 ± 104.353
  Blood Urea Nitrogen (BUN)                                HA       3         12.5 ± 7              13 ± 1.5            17 ± 4.5
  Calcium (Ca)                                             HA       3         8.5 ± 1.25            7 ± 1               8.8 ± 0.85
  Cholesterol                                              HA       3         56.5 ± 14.75          58 ± 13             73 ± 21
  Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb)   HA       3         0.3 ± 4.45            0.2 ± 0.4           0.3 ± 7.15
  Glutamine                                                HA       3         406.45 ± 97.249       344.31 ± 47.021     414.34 ± 24.774
  High Density Lipoprotein (HDL)                           HA       3         33 ± 5                27 ± 18             36 ± 6.75
  Histidine                                                HA       3         65.3 ± 0.404          61.03 ± 9.453       67.39 ± 8.07
  Lactate                                                  HA       3         0.84 ± 0.944          0.58 ± 0.942        3.47 ± 1.49
  Lysine                                                   HA       3         220.96 ± 66.163       181.93 ± 25.467     224.74 ± 13.38
  Phenylalanine                                            HA       3         65.09 ± 7.564         63.2 ± 3.598        67.17 ± 1.202
  Total CO2                                                HA       3         21 ± 1.5              19 ± 1.5            25 ± 3
  Total Protein (TP)                                       HA       3         5.3 ± 0.5             3.7 ± 0.7           4.7 ± 0.3
  Alkaline phosphatase (ALP)                               PV       3         174 ± 69              151 ± 33.5          184 ± 78
  Chloride (Cl)                                            PV       3         110 ± 14.5            109 ± 13            112 ± 7
  Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb)   PV       3         19.2 ± 13.25          9.2 ± 19.7          18.6 ± 15.85
  High Density Lipoprotein (HDL)                           PV       3         36 ± 12               33 ± 4.5            35.5 ± 2.5
  Histidine                                                PV       3         140.94 ± 16.226       120.93 ± 9.821      147.78 ± 19.839
  Lactate                                                  PV       3         1.07 ± 0.095          0.68 ± 0.632        4.38 ± 1.986
  Sodium (Na)                                              PV       3         146 ± 6.5             146 ± 12.5          149 ± 2.5
  Ornithine                                                PV       3         119.81 ± 4.751        107.16 ± 6.154      120.82 ± 17.96
  Proline                                                  PV       3         161.22 ± 18.151       162.06 ± 8.013      171.2 ± 35.127
  Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb)   SHVC     3         71.1 ± 6              59 ± 15.8           80 ± 13.45
  High Density Lipoprotein (HDL)                           SHVC     3         26.5 ± 6              24 ± 5              33 ± 0
  Histidine                                                SHVC     3         53.01 ± 9.45          52.2 ± 18.937       61.6 ± 6.314
  Lactate                                                  SHVC     3         1 ± 0.34              0.74 ± 0.141        3.81 ± 2.135
  Lysine                                                   SHVC     3         205.05 ± 79.978       197.38 ± 80.877     210.04 ± 29.84
  Sodium (Na)                                              SHVC     3         148 ± 7               148 ± 12.5          149 ± 7.5
  Partial pressure of CO2 (pCO2)                           SHVC     3         55.2 ± 6.9            51.3 ± 3.75         67.4 ± 7
  Total CO2                                                SHVC     3         22 ± 4                22 ± 2              25 ± 0.75
  Tyrosine                                                 SHVC     3         61.88 ± 6.68          61.29 ± 9.773       68.37 ± 7.3
  Acetoacetate                                             HA       4         116.29 ± 22.819       110.34 ± 47.623     70.65 ± 31.749
  Alanine                                                  HA       4         348.27 ± 41.954       297.32 ± 22.715     281.4 ± 33.083
  Albumin                                                  HA       4         1.95 ± 0.175          1.2 ± 0.3           1.3 ± 0.25
  Alanine Amino Transferase (ALT)                          HA       4         49.5 ± 14.25          36 ± 7.5            39 ± 11.5
  Ammonia                                                  HA       4         49.7 ± 4.527          37.3 ± 4.081        23.1 ± 4.616
  Asparagine                                               HA       4         41.98 ± 5.488         34.51 ± 3.945       32.73 ± 6.58
  Aspartate                                                HA       4         11.83 ± 1.549         9.25 ± 5.852        10.16 ± 2.637
  Hemoglobin (%)                                           HA       4         12.4 ± 1.35           12 ± 2.4            10.4 ± 1.05
  Flow Rate                                                HA       4         0.65 ± 0.146          0.5 ± 0.069         0.5 ± 0.426
  Glucose                                                  HA       4         169 ± 87              134 ± 46            146.5 ± 16
  Glutamate                                                HA       4         76.85 ± 6.662         54.15 ± 19.137      46.84 ± 17.453
  Glycine                                                  HA       4         216.75 ± 16.195       184.88 ± 25.974     163.76 ± 19.223
  Hematocrit                                               HA       4         36 ± 3.5              35 ± 7              31 ± 3
  Isoleucine                                               HA       4         113.82 ± 47.423       112.05 ± 19.396     108.01 ± 32.529
  Potassium (K)                                            HA       4         4.25 ± 2.15           4.2 ± 1.45          3.9 ± 0.75
  Leucine                                                  HA       4         369.7 ± 174.817       275.1 ± 32.956      285.2 ± 87.999
  Methionine                                               HA       4         52.33 ± 11.417        40.59 ± 8.321       38.75 ± 9.047
  Proline                                                  HA       4         164.52 ± 9.956        147.7 ± 27.492      147.69 ± 7.333
  Serine                                                   HA       4         223.83 ± 54.196       159.53 ± 12.872     169.06 ± 26.87
  Triglycerides (TG)                                       HA       4         62 ± 35.75            29 ± 7              26 ± 6
  Threonine                                                HA       4         256.03 ± 36.785       229.07 ± 41.332     202.04 ± 15.094
  Valine                                                   HA       4         234.98 ± 107.828      184.35 ± 36.559     178.74 ± 33.851
  Very low density lipoprotein (VLDL)                      HA       4         13 ± 0.5              6 ± 1               5 ± 0.5
  Albumin                                                  PV       4         2 ± 0.275             1.3 ± 0.35          1.3 ± 0.2
  Ammonia                                                  PV       4         108.65 ± 61.525       43.74 ± 33.121      72.67 ± 10.709
  Asparagine                                               PV       4         51.08 ± 6.886         32.09 ± 3.895       31.74 ± 0.837
  Aspartate                                                PV       4         19.18 ± 11.097        12.7 ± 1.594        12.06 ± 2.288
  Calcium (Ca)                                             PV       4         8.7 ± 2.25            8.3 ± 0.55          7.9 ± 1.65
  Hemoglobin (%)                                           PV       4         14.6 ± 0.95           13 ± 1.75           12.8 ± 0.5
  Glutamate                                                PV       4         63.16 ± 13.278        42.22 ± 11.148      48.44 ± 15.319
  Glutamine                                                PV       4         279.12 ± 59.911       253.05 ± 70.109     250.29 ± 33.243
  Glycine                                                  PV       4         273.49 ± 48.285       222.25 ± 33.939     204.59 ± 46.681
  Hematocrit                                               PV       4         43 ± 3.5              40 ± 5              38 ± 2.5
  Methionine                                               PV       4         44.77 ± 4.889         44.17 ± 4.749       43.82 ± 3.209
  Partial Oxygen pressure (PO2)                            PV       4         69.9 ± 11.75          54.2 ± 8.1          62.9 ± 15.65
  Serine                                                   PV       4         202.59 ± 14.805       148.88 ± 30.334     156.79 ± 14.701
  Triglycerides (TG)                                       PV       4         52 ± 43               25.5 ± 11.75        23 ± 2
  Total Protein (TP)                                       PV       4         5 ± 1.25              4.7 ± 0.9           4.8 ± 0.85
  Very low density lipoprotein (VLDL)                      PV       4         13 ± 5                6 ± 1               5 ± 0.5
  Alanine                                                  SHVC     4         246.38 ± 53.891       156.72 ± 42.529     152.26 ± 14.02
  Albumin                                                  SHVC     4         1.9 ± 0.25            1.3 ± 0.25          1.2 ± 0.25
  Alkaline phosphatase (ALP)                               SHVC     4         166 ± 67.5            129 ± 21            147 ± 82
  Alanine Amino Transferase (ALT)                          SHVC     4         40 ± 15.5             38 ± 14             37 ± 5.5
  Ammonia                                                  SHVC     4         40.44 ± 2.622         21.86 ± 10.951      15.01 ± 9.875
  Asparagine                                               SHVC     4         27.87 ± 1.556         20.1 ± 3.165        18.34 ± 0.097
  Aspartate                                                SHVC     4         13.57 ± 1.938         10.37 ± 4.932       8.47 ± 0.817
  β-hydroxybutyrate                                        SHVC     4         275.69 ± 457.311      257.28 ± 244.001    223.51 ± 174.944
  Calcium (Ca)                                             SHVC     4         8.6 ± 2.5             7.9 ± 0.3           8 ± 1.5
  Chloride (Cl)                                            SHVC     4         111 ± 14.5            110.5 ± 4.75        109 ± 11
  Hemoglobin (%)                                           SHVC     4         12.75 ± 0.875         10.7 ± 1.75         11.6 ± 0.65
  Fraction of Carboxyhemoglobin (FCOHb)                    SHVC     4         290 ± 73.75           130 ± 24            176 ± 50
  Glucose                                                  SHVC     4         263 ± 73              186 ± 72.5          152 ± 36.25
  Glutamate                                                SHVC     4         76.77 ± 43.277        49.62 ± 15.79       44.7 ± 19.093
  Glutamine                                                SHVC     4         299.7 ± 56.737        254.82 ± 97.786     228.06 ± 93.284
  Glycine                                                  SHVC     4         192.45 ± 57.864       148.04 ± 8.773      117.74 ± 58.252
  Hematocrit                                               SHVC     4         37.5 ± 2.5            31 ± 5              34 ± 1.5
  Methionine                                               SHVC     4         38.47 ± 1.541         32.45 ± 2.444       34.55 ± 1.049
  Phenylalanine                                            SHVC     4         54.68 ± 3.359         52.83 ± 15.86       49.57 ± 14.92
  Proline                                                  SHVC     4         137.82 ± 37.486       115.64 ± 6.032      113.16 ± 16.448
  Serine                                                   SHVC     4         166.82 ± 20.803       105.99 ± 12.727     92.92 ± 42.759
  Triglycerides (TG)                                       SHVC     4         25 ± 28.5             20 ± 3              20 ± 0
  Threonine                                                SHVC     4         198.18 ± 20.372       186.17 ± 59.461     157.26 ± 6.575
  Total Protein (TP)                                       SHVC     4         4.9 ± 1.05            4.3 ± 0.45          4 ± 0.85
  Very low density lipoprotein (VLDL)                      SHVC     4         9.5 ± 4.5             5 ± 0               5 ± 0

*Identification of Major Patterns*. While there are four major patterns in the metabolic response to burn, they are not necessarily independent. For instance, clusters 1 and 4 apparently display the inverse of the same response. To identify the number of independent patterns, SVD Analysis was employed. This analysis revealed that two patterns explained 98.6% of the total variability observed, indicating that the remaining two patterns were explainable within a margin of error of \<2%. The patterns highest weighted in SVD were clusters \#2 and \#4. It should be noted that the pattern selection here is based purely on overall trends, unlike the analysis of Yang *et al.* \[[@B34-metabolites-02-00458]\] which identifies critical time points of sudden changes in gene expression. Since the resolution of data for burn injury is limited (*i.e.*, we have only three levels of burn injury), it is not possible to employ a similar method to identify the degree of injury where the post-burn hypermetabolic response kicks in.

*Analysis of Cluster Membership*. In general there were no strong trends observed in the variables comprising the clusters ([Table 2](#metabolites-02-00458-t002){ref-type="table"}). Cluster 2 had nearly equal membership from all vessels. Cluster 4 had the most variables (68 total). Albumin, asparagine, aspartate, glutamate, methionine, serine, hematocrit, triglycerides and VLDL concentrations systemically (*i.e.*, in all vessels observed) were selected to cluster 4, which displayed a general decreasing response with increasing burn. pH and FO~2~Hb were in cluster 2, which showed a peak at 20% burn. Lactate had increased systemically and was in cluster 3 with a sharp increase at 40% burn; HDL and histidine also belonged in this cluster systematically, although the sharp increase at maximum burn was not present. LDL and cysteine increased systemically, and were in cluster 3.
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###### 

Cluster membership as a function of vessel/flux.

  Cluster   \# variables in vessel/flux                  
  --------- ----------------------------- ---- ---- ---- ----
  1         9                             20   15   9    45
  2         8                             10   6    8    26
  3         15                            9    9    15   36
  4         23                            16   25   23   68
  Total     55                            55   55   5    

To analyze the role of the liver in the dose response to burn injury, the variables that were selected to the same cluster in the liver inlet (PV and HA) but different outlet (SHVC) were identified. FCOHb (HA and PV in cluster 1, SHVC in cluster 4), pCO2 (2/3), ALP (3/4) were the three variables identified.

4.1. Model Selection and Index of Burn Injury Severity
------------------------------------------------------

The variable elimination process was performed with each model with the number of variables set at two. The two best models were the M5-Rules and NN, with very similar cross validation accuracies ([Table 3](#metabolites-02-00458-t003){ref-type="table"}). The formula for the index of burn injury severity developed via the NN model is:
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###### 

Comparison of tested models.

           Average Relative Accuracy   Variable 1          Variable 2
  -------- --------------------------- ------------------- ---------------------
  RBF      46.06 ± 4.59                Ammonia (HA)        Ornithine (SHVC)
  DT       70.54 ± 7.83                Asparagine (SHVC)   ALB (HA)
  M5P-DT   72.36 ± 1.03                ALB (HA)            Ammonia (HA)
  LR       73.28 ± 0.55                VLDL (HA)           Acetoacetate (SHVC)
  SMOR     75.92 ± 2.20                VLDL (HA)           Acetoacetate (SHVC)
  M5-R     87.82 ± 1.31                VLDL (HA)           Asparagine (SHVC)
  NN       87.89 ± 2.79                VLDL (HA)           Acetoacetate (SHVC)

An interesting observation was that very low density lipoprotein (VLDL) (cluster \#4) was a common choice in all the high-accuracy models. The acetoacetate level in the SHVC was the second selection in the NN model, whereas SHVC asparagine concentration was selected in the M5P-R model. The top two regression models, NN and M5P-R, had nearly identical \~88% cross validation accuracy, which has value as a diagnostic index, but with significant room for improvement.

The effects of using additional variables in the index were evaluated for NN and M5P-R ([Table 4](#metabolites-02-00458-t004){ref-type="table"}). The NN model was selected as the regression model of choice since accuracy increased significantly (23%) with up to 4 variables. By contrast, the accuracy of the M5P-R model was slightly increased with a third variable, but later decreased with addition of variables (it should be noted this is indeed the expected situation with proper cross-validation, which can account for over training; without validation data the accuracy would have increased monotonously with addition of new variables). The predictions of the NN model on a case-by-case basis are displayed in [Table 5](#metabolites-02-00458-t005){ref-type="table"}. However, note that these are the results of training on the full set of data, hence the overall accuracy is significantly higher than it would be expected in an actual application, which is what the cross validation results in [Table 3](#metabolites-02-00458-t003){ref-type="table"} report.
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###### 

Effect of number of variables on regression accuracy.

  Method               Measure                          2 Variables                                  3 Variables                                                  4 Variables                                                                    5 Variables
  -------------------- -------------------------------- -------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------ ---------------
  NN                   Average Relative Accuracy        87.89 ± 2.789                                89.46 ± 1.379                                                90.69 ± 1.508                                                                  89.18 ± 1.552
  Selected Variables   VLDL (HA), Acetoacetate (SHVC)   VLDL (HA), Acetoacetate (SHVC), pO2 (SHVC)   VLDL (SHVC), Acetoacetate (SHVC), pO2 (SHVC), CO2 (HA)       VLDL (SHVC), Acetoacetate (SHVC), pO2 (SHVC), Asparagine (SHVC), CO2 (HA)      
  M5-R                 Average Relative Accuracy        87.82 ± 1.312                                88.71 ± 0.983                                                87.66 ± 1.398                                                                  87.11 ± 1.038
  Selected Variables   VLDL (HA), Asparagine (SHVC)     Albumin (HA), Asparagine (SHVC), BUN (PV)    VLDL (HA), Acetoacetate (SHVC), Albumin (HA), pCO~2~(SHVC)   VLDL (HA), Acetoacetate (SHVC), Albumin (HA), pCO~2~(SHVC) Asparagine (SHVC)   
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###### 

Predictions of neural network model (Training on all data).

  Instance                    Burn % (actual)   Predictions                       
  --------------------------- ----------------- ------------- --------- --------- ----------
  1                           0                 0.132         0.324     1.35      1.271
  2                           0                 −0.281        −0.373    −0.423    −0.320
  3                           0                 3.003         0.109     0.05      −0.195
  4                           0                 −0.614        0.415     −0.632    −0.52 0a
  5                           0                 0.309         −0.713    −0.011    −0.013
  6                           0                 −0.416        −0.213    −0.451    −0.635
  7                           0                 −0.281        0.079     −0.301    −0.229
  8                           20                19.048        19.876    20.654    20.528
  9                           20                19.048        20.171    18.383    18.014
  10                          20                19.048        19.585    19.72     19.590
  11                          20                19.048        19.585    19.72     19.59 0
  12                          20                25.415        19.686    19.993    19.715
  13                          20                19.048        19.510    18.22     17.947
  14                          20                20.255        20.757    20.651    17.947
  15                          40                40.709        39.911    39.795    39.246
  16                          40                40.957        40.268    40.919    40.870
  17                          40                40.709        40.091    40.045    39.633
  18                          40                41.238        39.938    39.866    39.709
  19                          40                41.221        38.822    39.612    39.620
  20                          40                39.865        39.757    38.984    38.333
  21                          40                36.667        39.739    39.708    39.546
  *Relative Absolute Error*   *8.49%*           *2.54%*       *4.10%*   *5.04%*   

Finally, since selection of acetoacetate is highly significant as an indicator of mitochondrial redox potential, we also tested the prediction success when acetoacetate/β-hydroxybutyrate ratio (a commonly used predictor of redox potential) is used \[[@B38-metabolites-02-00458],[@B39-metabolites-02-00458]\]. Briefly, we repeated the variable selection/training algorithm for the following set: acetoacetate/β-hydroxybutyrate ratio (SHVC), acetoacetate/β-hydroxybutyrate ratio (HA), VLDL (SHVC), pO~2~ (SHVC), CO~2~ (HA), as well as acetoacetate/β-hydroxybutyrate ratio (SHVC) alone with NN and M5-R models. On its own, the acetoacetate/β-hydroxybutyrate ratio was extremely unsuccessful in predicting %TBSA, (average relative errors of 110.87 ± 7.444 and 110.26 ± 3.063 with NN and M5-R, respectively). Inclusion of other variables marginally improved the results but nowhere near the other results in [Table 4](#metabolites-02-00458-t004){ref-type="table"}: The average relative errors were 76.26 ± 15.887 and 64.55 ± 10.283 for NN and M5-R, respectively.

5. Discussion and Conclusions
=============================

The most important finding of this work is the strong correlation between VLDL levels and the extent of burn injury. Prior studies indicate that in burn trauma, VLDL secretion is impaired \[[@B40-metabolites-02-00458]\]. This is consistent with our observations that for increasing burn, there was a decrease in systemic VLDL. Interestingly, VLDL, LDL, HDL and TG are four of the relatively few variables that were systemically altered (*i.e.*, belonged in the same cluster independent of the measured blood vessel). However, the model developed here suggests that VLDL is the most preferred variable for building a predictor of severity of burn injury; ahead of other potential metabolic targets such as hyperglycemia which is correlated to insulin resistance \[[@B9-metabolites-02-00458]\], alanine/glucose (a systemic cycle for conversion of skeletal muscle to glucose during hypermetabolism), or even glutamine and arginine, which tend to be depleted after burn injury \[[@B5-metabolites-02-00458],[@B41-metabolites-02-00458],[@B42-metabolites-02-00458]\]. Of note here is that as clustering analysis shows, other potential variables identified in [Table 4](#metabolites-02-00458-t004){ref-type="table"} demonstrate altering (*i.e.*, belonging to different clusters based on measured vessel) injury dose-response profiles; therefore, predictions based on VLDL are least likely to be affected by tissue specific variations. Very likely, the fact that VLDL decrease is systemic also renders it a more accurate indicator of hypermetabolism.

The second variable of interest, which was selected commonly for most regression models (including M5P-R with 3 or more variables) is acetoacetate (SHVC), which in the context of burn is most important as the precursor for β-hydroxybutyrate. While ketone bodies are not a subject of intense focus in hypermetabolism, it was previously suggested that the acetoacetate/β-hydroxybutyrate ratio reflects the mitochondrial redox potential in the liver \[[@B43-metabolites-02-00458],[@B44-metabolites-02-00458]\], and in burn patients, a decrease of plasma acetoacetate to β-hydroxybutyrate ratio indicates mitochondrial dysfunction and correlates with developing multiple organ dysfunction \[[@B45-metabolites-02-00458]\]. Our rat data show a significant decrease in acetoacetate in the 40% TBSA burn group ([Table 1](#metabolites-02-00458-t001){ref-type="table"}). β-hydroxybutyrate was also decreased, although to a lesser extent, such that the acetoacetate to β-hydroxybutyrate ratio was decreased as well. In general, the decrease in total ketone bodies is regarded as an indicator of a limitation in oxidative phosphorylation after injury \[[@B46-metabolites-02-00458]\]. Concomitantly, other variables linked to mitochondrial activity or respiration, such as venous CO~2~, were also selected as additional injury indicators by the Neural Network model. It should be noted however, that the acetoacetate/β-hydroxybutyrate ratio by itself was not a particularly useful indicator of extent of burn injury. Further, replacing acetoacetate by the ratio severely decreased the accuracy achievable, with 100% error range, indicating that since the ratio was unsuccessful both on its own and when replacing acetoacetate concentrations, this reduction in accuracy is likely to be at least partially due to amplification or measurement noise. Note that β-hydroxybutyrate was one of the measurements with highest standard deviations relative to group means.

A third variable that was commonly selected was asparagine. Asparagine/aspartate is one of the cycles that carry amino acids from the muscle tissue to the liver during injury and was previously reported to be altered in rat models of burn injury \[[@B47-metabolites-02-00458]\]. While asparagine was able to replace acetoacetate in the M5P-R model, for the NN model that was ultimately more successful and could exceed 90% accuracy acetoacetate proved a better variable to include in the index.

It is worth noting that VLDL (SHVC) is not significantly different between the 20% and 40% burn groups, but is significantly reduced compared to the sham group. It can be argued that the ability to differentiate between sham and burn provided by VLDL complements acetoacetate (SHVC), which is different for the 40% burn group, but similar for the sham and 20% burn groups. The interesting note here is that neither of these variables is simply directly correlated to extent of burn, hence use of multiple variables is necessary. This supports our previous findings \[[@B21-metabolites-02-00458],[@B48-metabolites-02-00458]\] that there are significantly different responses observed between the 20% and 40% burn groups, either because the response at 20% TBSA is significantly less, or possibly as the 20% group is displaying a switch from hypermetabolism to a healing/normal phase as early as 4 days after burn injury. This response is likely the reason that a nonlinear model, such as the multi-layer perceptron, has higher accuracy than other linear models we tested in this study. This result may also justify why hypermetabolism diagnosis is still best based on clinical observations because this ad hoc method allows the physician to account for the nonlinear behavior based on past experience.

Using the 2-variable minimum identified by clustering, an index of burn injury severity was developed. The cross-validated accuracies of the best regression model, artificial Neural Network, was 88%. We also tested the inclusion of additional variables into the regression model. As displayed in [Table 4](#metabolites-02-00458-t004){ref-type="table"}, the accuracy of the multilayer perceptron model could be increased to up to 91% with the addition of arterial total CO~2~ (cluster 3) and venous oxygen (cluster 2). While the NN therefore did not include any variable from cluster 1, since cluster 4 displays the inverse dose-response to cluster 1 very closely, this confirms the previous analysis that 2 clusters are sufficient in capturing most of the metabolic response to increased burn injury.

From an application perspective, VLDL is in the same cluster systemically; hence point of measurement is unlikely to affect results significantly (repetition of 2-variable NN model with SHVC VLDL use led to only one rat in the sham burn group being significantly misclassified as 20% burn animal). Acetoacetate also displays a generally decreasing trend in all vessels. It should be noted that for an actual clinical index, ideally all measured variables will be systemically in the same cluster, as well as practical to measure. Most variables meet the criteria selected in the regression models. It is also likely possible to construct a regression model to predict unsuitable metabolites from more easy-to-measure ones, which we have not investigated here; a proper study of such an approach would require repetition of the experiments with tail-vein blood sample data complementing the HA, PV and SHVC samples to test if these less invasive samples correlate accurately to the data in this work.

To our knowledge this is the first attempt at creating a quantitative index of burn injury severity; however, it is important to realize the limitations in clinical applications. As the animals were not subjected to any intervention following burn injury, there were no potential confounding effects from nutritional supplementation, which may not be the case in human patients. Obviously, differences between rat and human metabolism, as well as effects of age and gender differences on the hypermetabolic response \[[@B48-metabolites-02-00458]\], will have to be considered for the development of a clinically applicable index.

These indicators of burn injury may provide insight and clues to new metabolic targets for therapy. In addition, the development of a quantitative score to identify the degree of hypermetabolism can ultimately provide a practical way to measure the patient response to injury and treatment. As the current diagnostic criteria are based purely on clinical observations, patient-to-patient variation in metabolism introduces a significant and undesirable degree of uncertainty in the care of the burn patient that could be avoided by such a quantitative index.
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